Cumberland Pharmaceuticals (CPIX) Free Cash Flow Growth (1y) (2011 - 2026)
Cumberland Pharmaceuticals (CPIX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.83 Bn | 32.09 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 44.93% |
| 10 | Cumberland Pharmaceuticals | 101.27 Mn | 90.27 Mn | 7.20 Mn | -89.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89.95% |
| Dec 31, 2025 | -99.84% |
| Sep 30, 2025 | -64.49% |
| Jun 30, 2025 | 194.72% |
| Mar 31, 2025 | 276.79% |
| Dec 31, 2024 | 91.87% |
| Sep 30, 2024 | -61.12% |
| Jun 30, 2024 | -116.71% |
| Mar 31, 2024 | -42.79% |
| Dec 31, 2023 | -73.85% |
| Sep 30, 2023 | -53.48% |
| Jun 30, 2023 | 135.41% |
| Mar 31, 2023 | -759.50% |
| Dec 31, 2022 | 10.17% |
| Sep 30, 2022 | 253.90% |
| Jun 30, 2022 | -18.29% |
| Mar 31, 2022 | -110.05% |
| Dec 31, 2021 | 325.79% |
| Sep 30, 2021 | -175.68% |
| Jun 30, 2021 | 89.57% |